Regeneron Pharmaceuticals (REGN) is returning from the Thanksgiving break with a hole in its drug research pipeline following the failure of the experimental eye drug nevascumab.
Across two mid-stage clinical trials, the addition of nevascumab to Eylea, Regeneron’s flagship product, failed to improve vision compared to Eylea alone, the company said Monday. The two studies were conducted in patients with diabetic macular edema and wet age-related macular degeneration. Based on these results, Regeneron and its development partner Bayer will not conduct phase 3 clinical trials of nevascumab.
The drug, an antibody that targets angiopoietin-2, was being developed in combination with Eylea to deliver added benefit to patients with vision-robbing eye diseases.
About the Author Reprints
